Scientist 1, In Vivo Pharmacology and Quantitative Biomarker

• Jul 2022 - Present

Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and pioneers in chemistry, technology, and the life sciences, with a deep bench of expertise in drug development and commercialization spanning from large pharma to biotech innovators. The company is based in Sunnyvale, CA. Show less

Scientist I, Immunology

• Dec 2021 - Jun 2022

Project Manager as Ph.D. Candidate

• Aug 2017 - Dec 2021

Projects Working as Lab and project manager:1. Identification of novel genes responsible for inhibitory control (Aug 2017 - December 2018). Run behavioral study with drosophila melanogaster model to identify which knockout gene or genes are important for our inhibitory control. 2. Comparison of cultured and bio-printed PC12 and MCF-7 cell-derived exosomes for 3D in-vitro models ( Aug 2018- September 2019). We have print live cancer cells in the medium and try to re-grow and compare with regular culture methods. 3. Targeted drug delivery for lung fibrosis treatment ( Aug 2019- ongoing). We utilize engineered exosomes to target fibrosis cells of animals and deliver BCL-2 inhibitors to evaluate therapeutic efficiency.4. Targeted drug delivery of BCL-2 inhibitors for cancer therapeutic efficiency ( December 2019- ongoing)5. Oral drug delivery against obesity and type-2 diabetic animal model ( January 2020 - ongoing) hypothesizes that oral delivery of ionic liquid improves the disease condition by fat trap or insulin delivery. 6. Ionic liquid for transdermal drug delivery ( skin melanoma and fibrosis) (ongoing), Our hypothesis here is an ionic liquid delivery ADC as immunotherapy against skin melanoma. Also, we are looking for we can inhibit metastasis in the melanoma model. We evaluate immune cell colony, organ deposition, 7. Oral Ionic Liquid delivery of small molecular to high cholesterol animal model. ( June 2020- present)8. Nano-Vesicle Based Anti-Fungal Formulation Shows Higher Stability, Skin Diffusion, Biosafety, and Anti-Fungal Efficacy In Vitro. 9. Immune cell exosome as an anti-cancer vaccine. Here we summarized the effectiveness of immune cell exosomes in activating immune response and inhibiting capacity in cancer invading mechanism. (submitted & under review) Show less

Graduate Research And Teaching Assistant

• Sep 2017 - Sep 2017

Laboratory Assistant

• Aug 2016 - Jul 2017

Teaching Assistant, Department of ECE Teaching Assistant, Department of ECE